Sign Up
Stories
Advancements in Cell Therapies and Sickle Cell Disease
Share
CASGEVY™ Gene-Edited Therapy Approval in...
Advancements in Cell Therapies and Sickl...
Advancements in Sickle Cell Disease Trea...
CASGEVY™: A Gene-Edited Therapy for Sick...
Overview
API
Orca Bio presents promising data at the 65th ASH Annual Meeting for its investigational high-precision cell therapies, Orca-T and Orca-Q, showcasing potential to expand treatment to additional patient groups. FDA approvals for gene therapies for sickle cell disease at ASH, with companies like Vertex Pharmaceuticals and Bluebird bio presenting updated data. A study suggests CAR-T cell therapy effective in treating autoimmune diseases. Additionally, a social media analysis highlights ongoing challenges in caring for people with sickle cell disease.
Ask a question
How can the challenges in caring for people with sickle cell disease be effectively addressed through advancements in healthcare and technology?
How might the potential of Orca-T and Orca-Q to expand treatment to additional patient groups impact the future of cell therapies?
What are the implications of the FDA approvals for gene therapies for sickle cell disease on the treatment landscape for patients?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage